Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 16/20 | 1.00 |
| ▸ | RNF114 | Q9Y508 | 3/20 | 0.86 |
| ▸ | BRD2 | P25440 | 4/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | TSPO | P30536 | 1/20 | 0.46 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.45 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.45 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.44 |
| ▸ | BRDT | Q58F21 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24076459 | 1.00 | BRD4 (1.00) | BRD4RNF114BRD2ADORA3TSPO | |
| SCHEMBL24076607 | 0.96 | BRD4 (0.93) | BRD4RNF114BRD2ADORA3TSPO | |
| SCHEMBL24075804 | 0.96 | BRD4 (0.93) | BRD4RNF114BRD2ADORA3TSPO | |
| SCHEMBL24076524 | 0.96 | BRD4 (0.93) | BRD4RNF114BRD2ADORA3TSPO | |
| SCHEMBL24075812 | 0.96 | BRD4 (0.93) | BRD4RNF114BRD2ADORA3TSPO | |
| SCHEMBL24076626 | 0.96 | BRD4 (0.93) | BRD4RNF114BRD2ADORA3TSPO | |
| SCHEMBL24076600 | 0.78 | RNF114 (0.65) | BRD4RNF114 | |
| SCHEMBL24076534 | 0.78 | RNF114 (0.65) | BRD4RNF114 | |
| SCHEMBL24076827 | 0.78 | RNF114 (0.66) | BRD4RNF114 | |
| SCHEMBL24076835 | 0.77 | RNF114 (0.67) | BRD4RNF114 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210369731-A1 | COVALENT TARGETING OF E3 LIGASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210369731-A1 | COVALENT TARGETING OF E3 LIGASES | RNF114, RNF4, RNF168 | BRD4 205/4885RNF114 1/4885BRD2 399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.